NCT07583823NARecruiting

Elevated Rate Pacing of Cardiac Amyloidosis

University of Minnesota

Start Date

10/10/2025

Completion Date

10/10/2026

Summary

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Adults 18 and older * Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee * Implanted Cardiac Pacemaker (+/- Defibrillator) * Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation * Non-dilated left ventricle by echocardiography * Ability to provide written consent * English Speaking Exclusion Criteria: * Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony) * Dilated left ventricle

Interventions

OTHER

Pacemaker Rate

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Cardiac AmyloidosisPacemaker

Locations

University of Minnesota

Minneapolis, Minnesota 55455

United States